Calcium kidney stone. Calculus of kidney
Conditions
Interventions
Intervention 1: Intervention group: Patients taking probiotic supplement made from strains selected in the study. Place of supplement production: Iranian society of probiotic and functional foods. Dur
Treatment - Drugs
Placebo
Intervention group: Patients taking probiotic supplement made from strains selected in the study. Place of supplement production: Iranian society of probiotic and functional foods. Duration and Dosage
Control group: Patients taking placebo. Place of placebo production: Iranian society of probiotic and functional foods. Duration and Dosage: One daily for 4 weeks
Sponsors
National Institute for Medical Research Developement
Urology and Nephrology Research Center
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with a history of at least 2 times of calcium (radiopaque) kidney stone episodes in recent 25 months (Recurrent stone former); at least 20 days since the last treatment they have; at least 3 months since following general dietary advice on recurrence prevention (drinking advice, high oxalate food restriction, animal protein restriction, fruit and vegetable intake encouragement, salt restriction and fat intake modification); age 18 to 65 years; Hyperoxaluria (24-hour urine oxalate over 40 and less than 80 mg); willingness to cooperate in the study. Exclusion criteria: Primary or enteric hyperoxaluria (urine oxalate>80 mg/24h); Taking any drugs which affects calcium metabolism, including thiazides; Taking any drugs which affects oxalate metabolism or calcium oxalate supersaturation, including vitamin B6; History of diabetes mellitus, hepatic failure, thyroid or parathyroid diseases, chronic kiodney disease (CKD), Urinary tract infection (UTI), chronic diarrhea or immunologic diseases; Pregnancy or lactation
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24 hour urine oxalate. Timepoint: Before the intervention, 4 weeks after the intervention, 8 weeks after intervention. Method of measurement: Enzymatic method.;Calcium oxalate supersaturation. Timepoint: Before the intervention, 4 weeks after the intervention, 8 weeks after intervention. Method of measurement: Calculation by LITHORISK software. | — |
Secondary
| Measure | Time frame |
|---|---|
| Stool oxalate. Timepoint: Before the intervention, 4 weeks after the intervention, 8 weeks after intervention. Method of measurement: Enzymatic method.;Stool lactobacillus count. Timepoint: Before the intervention, 4 weeks after the intervention, 8 weeks after intervention. Method of measurement: real-time PCR.;Stool bifidobacter count. Timepoint: Before the intervention, 4 weeks after the intervention, 8 weeks after intervention. Method of measurement: real-time PCR. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSanaz Tavasoli
Urology and Nephrology Research Center
Outcome results
None listed